Millennium Management LLC Grows Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)

Millennium Management LLC boosted its stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 1,864.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,827,280 shares of the biopharmaceutical company's stock after acquiring an additional 2,683,351 shares during the period. Millennium Management LLC owned 3.46% of ProQR Therapeutics worth $7,492,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. lifted its position in ProQR Therapeutics by 164.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after purchasing an additional 5,976,813 shares during the last quarter. Affinity Asset Advisors LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $7,486,000. Platinum Investment Management Ltd. bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $4,076,000. ArrowMark Colorado Holdings LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $3,131,000. Finally, DAFNA Capital Management LLC lifted its holdings in shares of ProQR Therapeutics by 73.1% in the 4th quarter. DAFNA Capital Management LLC now owns 1,567,561 shares of the biopharmaceutical company's stock worth $4,154,000 after acquiring an additional 661,979 shares during the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Up 2.4%

Shares of ProQR Therapeutics stock traded up $0.04 on Thursday, reaching $1.74. The stock had a trading volume of 410,255 shares, compared to its average volume of 631,576. The company has a 50 day moving average price of $1.46 and a 200 day moving average price of $2.24. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The stock has a market capitalization of $183.07 million, a P/E ratio of -5.44 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The firm had revenue of $4.89 million during the quarter, compared to analysts' expectations of $4.90 million. On average, analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PRQR shares. Chardan Capital restated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. Cantor Fitzgerald began coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price objective for the company. Evercore ISI began coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price objective for the company. HC Wainwright lifted their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Finally, Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.00.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).